737 related articles for article (PubMed ID: 10191211)
1. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease.
Meij P; Vervoort MB; Bloemena E; Schouten TE; Schwartz C; Grufferman S; Ambinder RF; Middeldorp JM
J Med Virol; 2002 Nov; 68(3):370-7. PubMed ID: 12226824
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
4. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens-induced by the virus.
Pearson G; Dewey F; Klein G; Henle G; Henle W
J Natl Cancer Inst; 1970 Nov; 45(5):989-95. PubMed ID: 18605425
[TBL] [Abstract][Full Text] [Related]
5. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
[TBL] [Abstract][Full Text] [Related]
6. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
7. CD4(+) T-cell responses to Epstein-Barr virus (EBV) latent membrane protein 1 in infectious mononucleosis and EBV-associated non-Hodgkin lymphoma: Th1 in active disease but Tr1 in remission.
Marshall NA; Culligan DJ; Johnston PW; Millar C; Barker RN; Vickers MA
Br J Haematol; 2007 Oct; 139(1):81-9. PubMed ID: 17854310
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
10. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients.
Whitney BM; Chan AT; Rickinson AB; Lee SP; Lin CK; Johnson PJ
J Med Virol; 2002 Jul; 67(3):359-63. PubMed ID: 12116028
[TBL] [Abstract][Full Text] [Related]
11. Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen.
Dong L; Masaki Y; Takegami T; Kawanami T; Itoh K; Jin ZX; Huang CR; Tong XP; Fukushima T; Tanaka M; Sawaki T; Sakai T; Sugai S; Okazaki T; Hirose Y; Umehara H
Int Immunol; 2007 Mar; 19(3):331-6. PubMed ID: 17272286
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody.
Piché A; Kasono K; Johanning F; Curiel TJ; Curiel DT
Gene Ther; 1998 Sep; 5(9):1171-9. PubMed ID: 9930317
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-related serology in Hodgkin's disease.
Henle W; Henle G
Natl Cancer Inst Monogr; 1973 May; 36():79-84. PubMed ID: 4355353
[No Abstract] [Full Text] [Related]
14. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma.
Marshall NA; Culligan DJ; Tighe J; Johnston PW; Barker RN; Vickers MA
Exp Hematol; 2007 Apr; 35(4):596-604. PubMed ID: 17379070
[TBL] [Abstract][Full Text] [Related]
15. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
16. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
17. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
18. Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma.
Hu L; Troyanovsky B; Zhang X; Trivedi P; Ernberg I; Klein G
Cancer Res; 2000 Oct; 60(19):5589-93. PubMed ID: 11034108
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2.
Longnecker R
Leukemia; 1994 Apr; 8 Suppl 1():S46-50. PubMed ID: 8152303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]